Fundamental Analysis of Sopharma AD (SFA:BLG) Stock
Fundamental analysis is the process of evaluating a security in an attempt to measure its intrinsic value by examining related economic, financial, and qualitative factors. This article provides a comprehensive fundamental analysis of Sopharma AD (SFA:BLG), one of the largest pharmaceutical companies in Bulgaria, traded on the Bulgarian Stock Exchange and the Warsaw Stock Exchange (WSE:SPH).
 |
| Fundamental Analysis of Sopharma AD (SFA:BLG) Stock |
I. Company and Industry Profile
Sopharma AD, founded in 1933, is a well-established company in the Pharmaceuticals & Biotechnology industry.
Core Business and Product Portfolio
Sopharma specializes in the production, distribution, and export of generic pharmaceutical products and finished drug forms. The company's diverse product portfolio includes:
Original Products: Notably, Tabex (for smoking cessation) and Tribestan (for male reproductive health stimulation).
Classic Generics: A wide range of medicines such as Analgin (painkiller), Tempalgin (painkiller), and Nivalin (for the peripheral nervous system).
Wholesale and Retail: Sopharma also has significant operations in the distribution and retail of pharmaceutical products, often through its subsidiary, Sopharma Trading AD.
Market Position and Geographical Reach
Sopharma is a dominant force in the Bulgarian and Eastern European pharmaceutical landscape. Key aspects of its market position include:
Domestic Dominance: It consistently ranks among the largest pharmaceutical companies in Bulgaria by revenue and is a major hospital supplier.
Export Focus: A substantial portion of the company's sales revenue (historically around 58% of its production business) is generated from export markets, primarily in Europe, but also increasingly in countries like Georgia, Azerbaijan, and Vietnam.
Fragmented Market: The local pharmaceutical market in Bulgaria is highly competitive and fragmented, but Sopharma has successfully maintained its competitive share.
II. Financial Health and Performance
Analyzing Sopharma's financial statements provides the foundation for determining its value and risk profile.
A. Revenue and Profitability
Sopharma has demonstrated a strong ability to grow its top line, though profitability can fluctuate.
| Metric | Trailing Twelve Months (TTM) (BGN) | Observation |
| Total Revenue (TTM) | ~2.41 billion | Strong revenue base, showing recent growth (e.g., 2024 revenue grew by 13.27% YoY). |
| Net Income (TTM) | ~102.39 million | Healthy earnings, though 2024 earnings saw a temporary decline, reflecting margin pressures or one-off events. |
| Gross Margin (TTM) | ~22.09% | A reasonable margin for a generic-focused pharmaceutical company. |
| Net Profit Margin (TTM) | ~4.24% | Indicates the percentage of revenue converted to profit. |
Efficiency Ratios (TTM):
Return on Equity (ROE): ~12.55%
Return on Assets (ROA): ~3.50%
An ROE of over 12% is generally considered good, suggesting efficient utilization of shareholder capital. However, the ROA is relatively lower, which is common in asset-heavy industries or companies with high total assets relative to net income.
B. Balance Sheet and Debt Analysis
The balance sheet is crucial for assessing financial resilience and risk.
| Metric | TTM/Recent Value | Observation |
| Total Debt/Equity Ratio | ~65.14% (or 0.67x) | This is a moderate, manageable level of debt, within acceptable limits for a growing company in this sector. |
| Current Ratio | ~1.30 | Indicates adequate short-term liquidity, suggesting the company can cover its current liabilities with current assets. |
| Quick Ratio | ~0.68 | This is below 1, which is common for companies with significant inventory (like pharmaceuticals) but suggests a slight reliance on inventory sales to meet short-term obligations. |
| Interest Coverage Ratio | ~5.68x | Strong coverage, meaning operating profit is more than five times the interest expense, indicating debt servicing is not an immediate concern. |
Note: Sopharma's reliance on debt financing (as reflected in the Net Debt to EBITDA ratio of ~3.94x) is higher than a debt-free peer, but the company's strong interest coverage mitigates this risk.
III. Valuation and Dividend Profile
Valuation metrics help determine if the stock is priced attractively relative to its financial performance.
A. Valuation Multiples
Sopharma appears to be reasonably or attractively valued compared to European industry averages.
| Metric | TTM/Recent Value | Comparative Analysis | Valuation Interpretation |
| Price-to-Earnings (P/E) Ratio | ~13.19 - 13.5x | This is generally below the average for the European Pharmaceuticals industry (often over 20x) and also below the broader Bulgarian market average. | Suggests the stock may be undervalued relative to its peers. |
| Price-to-Sales (P/S) Ratio | ~0.6x | A P/S ratio significantly below 1 often signals a deep discount, as the company's market capitalization is less than its annual sales. | Strongly indicates potential undervaluation. |
| Price-to-Book (P/B) Ratio | ~1.5x | Acceptable for a company with an ROE exceeding 12%. | The market is willing to pay 1.5 times the net asset value, reflecting its future earning potential. |
B. Dividend and Shareholder Returns
Sopharma is a consistent dividend payer, making it attractive for income-oriented investors.
Annual Dividend Yield (Trailing): ~1.91% (Note: Varies slightly depending on the reporting exchange/data source).
Dividend Payout Ratio: ~27.13%
A low payout ratio (less than 30%) is a strong indicator of dividend sustainability, as the company is retaining the majority of its earnings for reinvestment in growth, while still rewarding shareholders. Sopharma has also been active in share buy-backs, which further supports shareholder returns by reducing the share count.
IV. Risk Assessment and Final Conclusion
A. Key Risks
Regulatory Risk: The pharmaceutical industry is highly regulated. Changes in pricing, approval, or distribution policies in the EU or Eastern European markets could severely impact revenue and margins.
Product Risk: While diversified, the group's performance can be influenced by the success of key established brands like Tabex and Tribestan.
Macroeconomic and FX Risk: As a Bulgarian company with extensive exports, Sopharma is exposed to economic downturns in its key markets and fluctuations in foreign exchange rates, although the Bulgarian Lev (BGN) is pegged to the Euro.
Illiquidity: As with many stocks on the Bulgarian Stock Exchange, trading volume can be low, which may create difficulty for large institutional investors to trade efficiently.
B. Conclusion
Sopharma AD (SFA:BLG) presents a strong fundamental case for value investors in the European healthcare space.
The company operates with a robust revenue stream and healthy margins, and its moderate debt levels are well-covered by its operating profits. The valuation metrics, particularly the P/E and P/S ratios, suggest that the stock is attractively priced relative to its industry and peers. Additionally, the sustainable dividend provides an appealing income component.
While investors must acknowledge the inherent risks of the pharmaceutical industry (regulation, R&D) and the liquidity constraints of a smaller stock exchange, Sopharma's financial stability and competitive market position make it a strong candidate for an investor focused on fundamentals and long-term value.